{"id":"placebo-to-pentoxifylline-oral","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea"},{"rate":"2-5%","effect":"Dizziness"},{"rate":"2-5%","effect":"Headache"},{"rate":"1-3%","effect":"Tremor"},{"rate":"5-10%","effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pentoxifylline is a methylxanthine derivative that acts as a non-selective phosphodiesterase inhibitor and rheological agent. It enhances microcirculation by reducing blood viscosity, improving erythrocyte deformability, and decreasing platelet aggregation and fibrinogen levels. These effects improve oxygen delivery to tissues and reduce inflammatory responses.","oneSentence":"Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:58.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermittent claudication (peripheral arterial disease)"},{"name":"Diabetic angiopathies"},{"name":"Trophic disorders and ischemic ulcers"}]},"trialDetails":[{"nctId":"NCT06055257","phase":"PHASE3","title":"Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-01-16","conditions":"Osteoradionecrosis, Osteoradionecrosis of Jaw, Osteoradionecrosis of the Mandible","enrollment":24},{"nctId":"NCT03040778","phase":"PHASE3","title":"Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)","status":"ENROLLING_BY_INVITATION","sponsor":"University of Washington","startDate":"2018-04-01","conditions":"Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis","enrollment":100},{"nctId":"NCT06176339","phase":"PHASE2","title":"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients\"","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2023-12-15","conditions":"Breast Cancer Female","enrollment":70},{"nctId":"NCT04910178","phase":"PHASE4","title":"Follow-up of NAFLD Patients With MRI-PDFF","status":"COMPLETED","sponsor":"Asmaa Abdelfattah Elsayed","startDate":"2020-12-01","conditions":"Diabetes Type 2, NAFLD","enrollment":80},{"nctId":"NCT04094207","phase":"PHASE1, PHASE2","title":"Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-01-01","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT01337349","phase":"NA","title":"Effects of Pentoxiphylline on Left Ventricular (LV) Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure (CHF)","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2010-07","conditions":"Congestive Heart Failure","enrollment":""},{"nctId":"NCT05156684","phase":"NA","title":"Effect of Pentoxifylline and Zinc Co-administration in Patients With Oligoasthenoteratozoospermia","status":"UNKNOWN","sponsor":"Arak University of Medical Sciences","startDate":"2022-01-01","conditions":"Idiopathic Infertility","enrollment":140},{"nctId":"NCT02953275","phase":"EARLY_PHASE1","title":"Synergistic Effect of Vedolizumab and Pentoxifylline","status":"COMPLETED","sponsor":"University of Miami","startDate":"2017-04-13","conditions":"Crohn Disease","enrollment":37},{"nctId":"NCT02487225","phase":"PHASE3","title":"Pentoxifylline Treatment in Acute Pancreatitis (AP)","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-05","conditions":"Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis","enrollment":83},{"nctId":"NCT03591536","phase":"NA","title":"Effects of Pentoxifylline After Cardiac Surgery","status":"COMPLETED","sponsor":"nooshin dalili","startDate":"2017-01-01","conditions":"Oxidative Stress, AKI, Inflammation","enrollment":100},{"nctId":"NCT02451774","phase":"PHASE2, PHASE3","title":"Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction","status":"UNKNOWN","sponsor":"Ramón Óscar González-Ramella, Ph.D","startDate":"2015-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":44},{"nctId":"NCT02992678","phase":"EARLY_PHASE1","title":"Pentoxifylline for the Prevention of PEP","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2016-12","conditions":"Pancreatitis","enrollment":110},{"nctId":"NCT01292005","phase":"EARLY_PHASE1","title":"Pentoxifylline Treatment of Acute Pancreatitis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-04","conditions":"Acute Pancreatitis","enrollment":28},{"nctId":"NCT01464242","phase":"PHASE2, PHASE3","title":"Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Centro Internacional de Entrenamiento e Investigaciones Médicas","startDate":"2011-11","conditions":"Cutaneous Leishmaniasis","enrollment":75},{"nctId":"NCT00561093","phase":"PHASE3","title":"Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2008-02","conditions":"Hypoalbuminemia, Protein-energy Malnutrition, Inflammation","enrollment":93},{"nctId":"NCT01263925","phase":"PHASE3","title":"Prostaglandin E1 in Outpatients With Intermittent Claudication","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-04","conditions":"Stage II Peripheral Arterial Occlusive Disease, Intermittent Claudication Fontaine Stage II PAOD","enrollment":561},{"nctId":"NCT00205049","phase":"PHASE1","title":"Pentoxifylline for Acute Alcoholic Hepatitis (AAH)","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2005-03","conditions":"Hepatitis, Alcoholic","enrollment":4},{"nctId":"NCT02008214","phase":"PHASE4","title":"Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2013-12","conditions":"Hepacivirus, HIV Infections","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Pentoxifylline oral","genericName":"Placebo to Pentoxifylline oral","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation. Used for Intermittent claudication (peripheral arterial disease), Diabetic angiopathies, Trophic disorders and ischemic ulcers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}